Massive partnerships Iktos is actively expanding through high-value collaborations with large pharma companies such as Servier and Pierre Fabre, presenting a clear sales opportunity to offer integrated AI-driven drug discovery solutions and joint development programs.

Integrated AI + robotics The combination of AI design platforms, Spaya retrosynthesis, and Iktos Robotics enables a faster design–make–test cycle, creating a compelling value proposition for partners seeking accelerated timelines and reduced R&D risk.

PPI and RPI focus Acquisition of Synsight strengthens capabilities in Protein-Protein Interactions and RNA-Protein Interactions biology, opening opportunities to target niche, high-impact drug discovery programs and expand into biology-led collaboration models.

Substantial funding momentum Recent EIC Accelerator grant and ongoing international partnerships signal strong investor and ecosystem support, which can help in de-risking large-scale customer projects and unlocking co-funded opportunities.

Global pharma alignment Multi-year, high-potential deals with Servier and ongoing engagements with major players indicate readiness for enterprise-level deployments, suggesting scalable commercial models for tiered SaaS and integrated services.